



Press release

Stockholm, November 27, 2009

Affibody Nominated for Swedish Innovation Award

STOCKHOLM, Sweden – November 27, 2009. Affibody has been appointed as one of the eight final nominees to the Swedish Innovation Award 2009

The Swedish Innovation Award was founded by the Swedish business magazine Veckans Affärer and consulting firm ÅF Group and is awarded to the innovator of the year in Sweden.

”We are honored to be among the final nominees of this award which we see as recognition of the considerable scientific achievements of the company and its founders“, says David Beijker, President and CEO of Affibody.

The following companies have been nominated:

- Aerocrine AB
- Affibody AB
- Chromogenics AB
- Diamorph AB
- Ergonomidesign AB
- Forskningsprojektet Aware
- Glo AB
- SKF AB

The award ceremony will take place at the Stockholm Concert Hall on December 2, 2009.

Read more about the award at: <http://www.va.se/event/innovationspriset/>

About Affibody

Affibody is a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody® molecules, which are small, robust and easily produced, can be designed to bind specifically to a large number of target proteins. They have a broad range of applications including protein purification, enzyme inhibition, research reagents for protein capture and detection, diagnostics, including molecular imaging, and targeted therapeutics.

Affibody is also commercializing Albumod™, a unique albumin binding technology designed to enhance the efficacy of biotherapeutics by extending their circulation time.

Affibody has already developed biotechnological products that are commercialized by GE, Agilent and Finnzymes, and is developing molecules for therapeutic application in collaboration with Biovitrum.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include the investment companies HealthCap and Investor Growth Capital. Further information can be found at: www.affibody.com.

For more information please contact:

Affibody

David Bejker, CEO

Cell phone: +46 706 454 948

david.bejker@affibody.com

Johan Stuart, CFO

Cell phone: +46 706 644 096

johan.stuart@affibody.com